Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis.
Saved in:
| Title: | Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. |
|---|---|
| Authors: | Babu S; Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA., Macklin EA; Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Jackson KE; Office of the Prescription Drug Monitoring Program, Maryland Department of Health, Baltimore, MD, USA., Simpson E; McCance Center for Brain Health at Massachusetts General Hospital, Boston, MA, USA., Mahoney K; Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA., Yu H; Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA., Walker J; Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA., Simmons Z; Penn State Health Hershey Medical Center, Hershey, PA, USA., David WS; Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA., Barkhaus PE; Medical College of Wisconsin, Milwaukee, WI, USA., Simionescu L; SUNY Upstate Medical Center, Syracuse, NY, USA., Dimachkie MM; University of Kansas Medical Center, Kansas City, KS, USA., Pestronk A; Washington University School of Medicine, St. Louis, MO, USA., Salameh JS; American University of Beirut Medical Center, Beirut, Lebanon., Weiss MD; University of Washington Medical Center, Seattle, WA, USA., Brooks BR; Atrium Health Neurosciences Institute, Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte, NC, USA, and., Schoenfeld D; Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Shefner J; Barrow Neurological Institute and University of Arizona College of Medicine, Phoenix, AZ, USA., Aggarwal S; Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA., Cudkowicz ME; Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA., Atassi N; Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA. |
| Source: | Amyotrophic lateral sclerosis & frontotemporal degeneration [Amyotroph Lateral Scler Frontotemporal Degener] 2020 Feb; Vol. 21 (1-2), pp. 15-23. Date of Electronic Publication: 2019 Oct 14. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101587185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2167-9223 (Electronic) Linking ISSN: 21678421 NLM ISO Abbreviation: Amyotroph Lateral Scler Frontotemporal Degener Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2167-9223 |
|---|---|
| DOI: | 10.1080/21678421.2019.1672750 |
